- 全部删除
- 您的购物车当前为空
TrkA-IN-9 (VMD-928) 是一种选择性、口服可用的原肌球蛋白受体激酶 A (TrkA) 抑制剂。它通过阻断神经生长因子 (NGF) 与 TrkA 的结合引发的下游信号通路,抑制细胞增殖和侵袭,促进癌细胞死亡。TrkA-IN-9 有潜力用于多种癌症的研究,包括前列腺癌、胸腺癌、间皮瘤、头颈部鳞状细胞癌、肺癌、卵巢癌和肝细胞癌。
TrkA-IN-9 (VMD-928) 是一种选择性、口服可用的原肌球蛋白受体激酶 A (TrkA) 抑制剂。它通过阻断神经生长因子 (NGF) 与 TrkA 的结合引发的下游信号通路,抑制细胞增殖和侵袭,促进癌细胞死亡。TrkA-IN-9 有潜力用于多种癌症的研究,包括前列腺癌、胸腺癌、间皮瘤、头颈部鳞状细胞癌、肺癌、卵巢癌和肝细胞癌。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 待询 | 10-14周 | |
50 mg | 待询 | 10-14周 |
TrkA-IN-9 相关产品
产品描述 | TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma. |
分子量 | 524.61 |
分子式 | C31H32N4O4 |
CAS No. | 1802770-18-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容